PDF herunterladen
Nervenheilkunde 2014; 33(07/08): 535-539
DOI: 10.1055/s-0038-1627709
Fortbildung Karlsruhe
Schattauer GmbH

Chronisch inflammatorische demyelinisierende Polyneuropathie

Aktuelle Entwicklungen bei Diagnose und TherapieRecent developments in diagnosis and therapy of chronic inflammatory demyelinating polyneuropathy
H. C. Lehmann
1   Klinik und Poliklinik für Neurologie, Uniklinik Köln
› Institutsangaben
Weitere Informationen

Publikationsverlauf

eingegangen am: 10. Februar 2014

angenommen am: 27. Februar 2014

Publikationsdatum:
24. Januar 2018 (online)

    Lizenzen und Reprints

Zusammenfassung

Die chronisch inflammatorische demyelinisierende Polyneuropathie (CIDP) ist eine sporadisch auftretende, chronisch progredient oder schubförmige verlaufende entzündliche periphere Neuropathie. Klinische und experimentelle Daten belegen, dass die CIDP eine autoimmun-vermittelte Neuropathie ist, bei der eine aberrante humorale und zelluläre Immunantwort gegen Bestandteile peripherer Nerven entscheidend beteiligt sind. In den vergangenen Jahren sind weitere Erkenntnisse hinsichtlich der Epidemiologie und der Pathogenese dieser Erkrankung erzielt worden. Von klinischer Seite wird zunehmend der Stellenwert bildgebende Verfahren zur Diagnostik der CIDP wissenschaftlich untersucht. Ergänzt werden diese Fortschritte durch die Ergebnisse neuerer Therapiestudien, die zu einer Verbesserung der Langzeitbehandlung von CIPD-Patienten führen. Die vorliegende Arbeit gibt einen Überblick über diese neuesten Entwicklungen auf dem Gebiet der CIDP.

Summary

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a sporadically occurring, chronic progressive or relapsing inflammatory peripheral neuropathy. There is clinical and experimental evidence that CIDP is caused by an aberrant humoral and cellular immune response against components of peripheral nerve tissue. In the last years substantial progress has been made for further characterization of the epidemiology and the pathogenesis of the disease. Likewise, there are clinical approaches that are aimed to decipher the utility of nerve imaging as additional diagnostic measure in CIDP. These advancements are complemented by the results from recent treatment trials that will help to optimize long-term treatment of CIDP patients. This review summarizes some of those recent developments in the field of CIDP.

Schlüsselwörter

Neuropathie - Immunglobuline - Inflammation

Keywords

Neuropathy - immunoglobulins - inflammation
 

  • Literatur

  • 1 Lehmann HC. et al. Pathogenesis and treatment of immune-mediated neuropathies. Ther Adv Neurol Dis 2009; 02: 261-281.
    CrossrefPubMedGoogle Scholar
  • 2 Mygland A, Monstad P. Chronic polyneuropathies in vest-agder, norway. Eur J Neurol 2001; 08: 157-165.
    CrossrefPubMedGoogle Scholar
  • 3 Kusumi M. et al. Epidemiology of inflammatory neurological and inflammatory neuromuscular diseases in tottori prefecture, japan. Psychiatry Clin Neurosci 1995; 49: 169-174.
    CrossrefPubMedGoogle Scholar
  • 4 Iijima M. et al. Prevalence and incidence rates of chronic inflammatory demyelinating polyneuropathy in the japanese population. J Neurol Neurosurg Psychiatry 2008; 79: 1040-1043.
    CrossrefPubMedGoogle Scholar
  • 5 Mahdi-Rogers M, Hughes RA. Epidemiology of chronic inflammatory neuropathies in south-east england. Eur J Neurol 2014; 21: 28-33.
    CrossrefPubMedGoogle Scholar
  • 6 Laughlin RS. et al. Incidence and prevalence of cidp and the association of diabetes mellitus. Neurology 2009; 73: 39-45.
    CrossrefPubMedGoogle Scholar
  • 7 Vallat JM, Sommer C, Magy L. Chronic inflammatory demyelinating polyradiculoneuropathy: Diagnostic and therapeutic challenges for a treatable condition. Lancet Neurol 2010; 09: 402-412.
    CrossrefPubMedGoogle Scholar
  • 8 Sasaki M, Ohara S, Oide T, Hayashida K, Hayashi R. An autopsy case of chronic inflammatory demyelinating polyradiculoneuropathy with respiratory failure. Muscle Nerve 2004; 30: 382-387.
    CrossrefPubMedGoogle Scholar
  • 9 Chiang MC. et al. Cutaneous innervation in chronic inflammatory demyelinating polyneuropathy. Neurology 2002; 59: 1094-1098.
    CrossrefPubMedGoogle Scholar
  • 10 Kim HJ, Jung CG, Jensen MA, Dukala D, Soliven B. Targeting of myelin protein zero in a spontaneous autoimmune polyneuropathy. J Immunol 2008; 181: 8753-8760.
    CrossrefPubMedGoogle Scholar
  • 11 Ubogu EE, Yosef N, Xia RH, Sheikh KA. Behavioral, electrophysiological, and histopathological characterization of a severe murine chronic demyelinating polyneuritis model. J Peripher Nerv Syst 2012; 17: 53-61.
    CrossrefPubMedGoogle Scholar
  • 12 Winer J, Hughes S, Cooper J, Ben-Smith A, Savage C. Gamma delta t cells infiltrating sensory nerve biopsies from patients with inflammatory neuropathy. J Neurol 2002; 249: 616-621.
    CrossrefPubMedGoogle Scholar
  • 13 Sainaghi P. et al. The expression pattern of inflammatory mediators in cerebrospinal fluid differentiates guillain-barré syndrome from chronic inflammatory demyelinating polyneuropathy. Cytokine 2010; 51: 138-143.
    CrossrefPubMedGoogle Scholar
  • 14 Csurhes PA. et al. T cell reactivity to p0, p2, pmp-22, and myelin basic protein in patients with guillain-barre syndrome and chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry 2005; 76: 1431-1439.
    CrossrefPubMedGoogle Scholar
  • 15 Lehmann HC. et al. Plasma exchange in neuroimmunological disorders. Part 2 treatment of neuromuscular disorders. Arch Neurol 2006; 63: 1066-1071.
    CrossrefPubMedGoogle Scholar
  • 16 Benedetti L. et al. Rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: A report of 13 cases and review of the literature. J Neurol Neurosurg Psychiatry 2011; 82: 306-308.
    CrossrefPubMedGoogle Scholar
  • 17 Yan WX. et al. Passive transfer of demyelination by serum or igg from chronic inflammatory demyelinating polyneuropathy patients. Ann Neurol 2000; 47: 765-775.
    CrossrefPubMedGoogle Scholar
  • 18 Sanvito L. et al. Humoral and cellular immune responses to myelin protein peptides in chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry 2009; 80: 333-338.
    CrossrefPubMedGoogle Scholar
  • 19 Sanvito L. et al. Circulating subsets and cd4(+) cd25(+) regulatory t cell function in chronic inflammatory demyelinating polyradiculoneuropathy. Autoimmunity 2009; 42: 667-677.
    CrossrefPubMedGoogle Scholar
  • 20 Querol L. et al. Antibodies to contactin-1 in chronic inflammatory demyelinating polyneuropathy. Ann Neurol 2013; 73: 370-380.
    CrossrefPubMedGoogle Scholar
  • 21 PNS JTFotEat. European federation of neurological societies/peripheral nerve society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint task force of the european federation of neurological societies and the peripheral nerve society – first revision. J Peripher Nerv Syst 2010; 15: 1-9.
    CrossrefPubMedGoogle Scholar
  • 22 Breiner A, Brannagan TH. Comparison of sensitivity and specificity among 15 criteria for chronic inflammatory demyelinating polyneuropathy. Muscle Nerve. 2013 doi: 10.1002/mus.24088.
    PubMedGoogle Scholar
  • 23 Mathys C. et al. Peripheral neuropathy: Assessment of proximal nerve integrity by diffusion tensor imaging. Muscle Nerve 2013; 48: 889-896.
    CrossrefPubMedGoogle Scholar
  • 24 Kakuda T. et al. Diffusion tensor imaging of peripheral nerve in patients with chronic inflammatory demyelinating polyradiculoneuropathy: A feasibility study. Neuroradiology 2011; 53: 955-960.
    CrossrefPubMedGoogle Scholar
  • 25 Goedee HS, Brekelmans GJ, Visser LH. Multifocal enlargement and increased vascularization of peripheral nerves detected by sonography in cidp: A pilot study. Clin Neurophysiol 2013; 125: 154-159.
    PubMedGoogle Scholar
  • 26 Kerasnoudis A. Nerve ultrasound in a case of chronic inflammatory demyelinating neuropathy. Muscle Nerve 2013; 47: 443-446.
    CrossrefPubMedGoogle Scholar
  • 27 Gorson KC. et al. Chronic inflammatory demyelinating polyneuropathy disease activity status: Recommendations for clinical research standards and use in clinical practice. J Peripher Nerv Syst 2010; 15: 326-333.
    CrossrefPubMedGoogle Scholar
  • 28 Hartung HP, Lehmann HC, Willison HJ. Peripheral neuropathies: Establishing common clinical research standards for cidp. Nat Rev Neurol 2011; 07: 250-251.
    CrossrefPubMedGoogle Scholar
  • 29 Cocito D. et al. A nationwide retrospective analysis on the effect of immune therapies in patients with chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol 2010; 17: 289-294.
    CrossrefPubMedGoogle Scholar
  • 30 Tackenberg B. et al. Classifications and treatment responses in chronic immune-mediated demyelinating polyneuropathy. Neurology 2007; 68: 1622-1629.
    CrossrefPubMedGoogle Scholar
  • 31 Chan Y, Allen D, Fialho D, Mills K, Hughes R. Predicting response to treatment in chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry 2006; 77: 114-116.
    CrossrefPubMedGoogle Scholar
  • 32 Kuwabara S. et al. Long term prognosis of chronic inflammatory demyelinating polyneuropathy: A five year follow up of 38 cases. J Neurol Neurosurg Psychiatry 2006; 77: 66-70.
    CrossrefPubMedGoogle Scholar
  • 33 van Schaik IN. et al. Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (predict study): A doubleblind, randomised, controlled trial. Lancet Neurol 2010; 09: 245-253.
    CrossrefPubMedGoogle Scholar